The BioIndustry Association (BIA) welcomes the finalisation of the Pharmaceutical Price Regulation Scheme (PPRS) negotiation process and the proposed recommendations around the flexible options for market access. The flexible options for market access build on the central principle of freedom of pricing and could facilitate clinical development of biological medicines that have already been approved for one indication in other indications. This will help patients have faster access to much-needed treatments.
Aisling Burnand, Chief Executive of the BioIndustry Association said:
“The sudden renegotiation of the PPRS came as a shock to the industry. However the Department of Health has recognised the need to encourage innovation and the role that smaller companies play. Therefore the BIA welcomes the increase in the Annual Financial Return threshold from £25 million to £35 million which comes in addition to the small company exemption announced in the June Heads of Agreement.
“The new deal not only delivers cost savings for the NHS and helps patients gain earlier access to innovative treatments but also recognises the contribution smaller companies can make to healthcare in the UK.”
BioIndustry Association
Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.
With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society. For further information, please go to: www.bioindustry.org
